IGC-AD1:
Bringing Hope to Alzheimer's Agitation
IGC-AD1 represents an innovative therapeutic approach to one of the most challenging symptoms of Alzheimer’s disease—agitation. This investigational therapy aims to deliver relief for patients while easing the emotional burden on caregivers and families.
For Physicians
Clinical insights and trial detailss
Learn More →
For Families
Support and educational resourcess
Learn More →IGC-AD1 is designed to target neuroinflammation, potentially stabilize cannabinoid receptor type 1 (CB1R) activity, and address neurotransmitter imbalances—key biological mechanisms implicated in agitation in Alzheimer’s dementia.
Phase 1 and Phase 2 trials are registered on ClinicalTrials.gov.
A Novel Approach to Alzheimer's Agitation
Agitation affects up to 76% of people living with Alzheimer’s disease, causing significant distress for patients and placing an overwhelming burden on caregivers.
Current treatment options are limited and often associated with side effects, leaving families in urgent need of better solutions.
Our Breakthrough Solution
IGC-AD1 is an investigational oral liquid formulation developed to manage agitation in Alzheimer’s disease.
Our unique dual-API approach targets multiple neurobiological pathways involved in neuropsychiatric symptoms, potentially offering better tolerability and enhanced therapeutic outcomes compared to existing treatments.
Behind IGC-AD1
IGC-AD1 is being studied under an FDA Investigational New Drug (IND) application.
Designed to target pathways implicated in agitation: neuroinflammation, CB1 receptor signaling, and neurotransmitter regulation.
Easy-to-administer oral liquid formulation.
IGC-AD1 was safe and well tolerated at three dosage levels in the Phase 1 study.
The CALMA Phase 2 randomized, double-blind study is currently evaluating efficacy and safety in a multicenter trial.
From Discovery to Trials: A Path Toward Treating Alzheimer’s Agitation
Preclinical
Preclinical studies identified the potential of IGC-AD1’s active ingredients to act as an AD-modifying drug. In lab models, the combination of APIs reduced Aβ aggregation, maintained APP levels, and improved mitochondrial function.
Phase I
The Phase 1 trial evaluated IGC-AD1 in participants with mild to moderate Alzheimer’s disease to assess safety and tolerability. Results showed IGC-AD1 was safe at all three dosage levels, and improvements were observed in neuropsychiatric symptoms and caregiver distress.
Phase II: CALMA
The ongoing CALMA Phase 2 clinical trial is evaluating the efficacy of IGC-AD1 for agitation in Alzheimer’s dementia across multiple sites in the U.S. and Canada, bringing new hope to patients and caregivers.
Join CALMA Trial
A trial evaluating an investigational treatment for agitation in Alzheimer’s disease. Together, we can advance new therapeutic possibilities and bring hope to those affected.
